Kangmei Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 600518.SS

Kangmei Pharmaceutical Co., Ltd. Price to Earnings Ratio (P/E) on January 14, 2025: 293.26

Kangmei Pharmaceutical Co., Ltd. Price to Earnings Ratio (P/E) is 293.26 on January 14, 2025, a 118.58% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Kangmei Pharmaceutical Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is 378.08 on December 09, 2024, which is 28.92% above the current Price to Earnings Ratio (P/E).
Kangmei Pharmaceutical Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is 124.64 on June 25, 2024, which is -57.50% below the current Price to Earnings Ratio (P/E).
Kangmei Pharmaceutical Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is 196.78.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Shanghai Stock Exchange: 600518.SS

Kangmei Pharmaceutical Co., Ltd.

CEO	Mr. Guowei Liu
IPO Date	March 19, 2001
Location	China
Headquarters	East side of Jieshen Road
Employees	4,409
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese medicines in China. It also offers chemical drug products; and operates hospitals and Chinese medicine pharmacies. The company was founded in 1997 and is headquartered in Puning, China.

Key trends

Past 5 years